01-06-2012: Molecular Partners AG announced the appointment of Lisa Rojkjaer, MD as Chief Medical Officer, strengthening the existing management team.
Dr. Rojkjaer holds a medical degree from the University of Toronto and is a board-certified hematologist with over 10 years experience in drug development and commercialization in the biotech and pharma industries. She will be heading up all clinical activities at Molecular Partners by identifying and prioritizing clinical development programs of Molecular Partners in order to broaden the company’s pipeline.
Prior to joining Molecular Partners, Dr. Rojkjaer led all proprietary clinical development programs as Vice President and Head of Clinical Development at Morphosys AG in Germany. Previously, Dr. Rojkjaer held a variety of senior positions in clinical development and medical affairs. She served as a Global Clinical Program Head in oncology development, and more recently as EU Head of Medical Affairs, Hematology at Novartis. Prior to Novartis, she spent five years with Novo Nordisk as the Head of Global Medical Affairs, Biopharmaceuticals in Denmark and later, Director of Clinical Development, Hematology in the US. In these positions, Dr. Rojkjaer was responsible for development of products and product candidates in early and late (phase I-IV) development stages.
Molecular Partners announced that the results of a Phase I/II study evaluating the safety and preliminary activity of MP0112, a long-acting anti-VEGF DARPin, in patients with Diabetic Macular Edema (DME) have been published in The American Journal of Ophthalmology (AJO).
MP0112 was shown to ... more
Allergan, Inc. and Molecular Partners AG announced that they have significantly expanded their existing relationship by entering into two separate agreements to discover, develop, and commercialize proprietary therapeutic DARPin® products for the treatment of serious ophthalmic diseases.Mol ... more
Molecular Partners AG announced the appointment of Lisa Rojkjaer, MD as Chief Medical Officer, strengthening the existing management team.Dr. Rojkjaer holds a medical degree from the University of Toronto and is a board-certified hematologist with over 10 years experience in drug developmen ... more
Molecular Partners is a privately held biotech company focusing on the commercialization of a novel class of biological drugs known as DARPins. Molecular Partners holds the exclusive patent rights for full freedom to operate with DARPins for all applications.
Molecular Partners has enginee ... more